Skip to main content Accessibility help
×
Home
  • Print publication year: 2010
  • Online publication date: September 2011

Chapter 36 - Ultrasonography in the prediction and management of ovarian hyperstimulation syndrome

from Section 4: - Early pregnancy after infertility treatment

Summary

During the preclinical development of in-vitro fertilization (IVF) in the human, oocytes were frequently obtained at laparotomies for various indications and the time for the operative procedure was generally not scheduled close to ovulation. The ovaries could now easily be scanned without using the full-bladder technique, and transvaginal ultrasound-guided oocyte retrieval (TVOR) could generally be performed with only use of some sedative in combination with local anesthesia. In order to increase the oocyte recovery rate it was found that Teflon tubing between needle and sampling tube was optimal. Today there are various sampling sets commercially available, including needle, tubing, and sampling tubes. The different complications of TVOR are bleeding and infection. In conclusion, available data regarding possible adverse effects of ultrasonography on oocytes have been interpreted to indicate that the technique, in this respect, is as safe as laparoscopy.

References

1. RabauE, SerrDM, DavidA, et al. Human menopausal gonadotrophin for anovulation and sterility. Am J Obstet Gynecol 1967; 98: 92–8.
2. SchenkerJG, WeinsteinD. Ovarian hyperstimulation syndrome: a current survey. Fertil Steril 1978; 30: 255–68.
3. GolanA, Ron-ElR, HermanA, et al. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 1989; 44: 430–40.
4. NavotD, BerghPA, LauferN. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992; 58: 249–61.
5. MozesM, BogowskyH, AntebyE, et al. Thrombo-embolic phenomena after ovarian stimulation with human menopausal gonadotrophins. Lancet 1965; 2: 1213–15.
6. RizkB. Classification of ovarian hyperstimulation syndrome. In: RizkB, ed. Ovarian Hyperstimulation Syndrome: Epidemiology, Pathophysiology, Prevention and Management. Chapter 1. New York and Cambridge: Cambridge University Press, 2006; 1–9.
7. SerourG. Ovarian hyperstimulation syndrome In: GerrisJ, OlivennesF, DelvigneA, eds. Ovarian Hyperstimulation Syndrome. London: Taylor and Francis, 2006.
8. SchenkerJG. Ovarian hyperstimulation syndrome. In: WallachEE, ZacurHA, eds. Reproductive Medicine and Surgery. Chapter 35. St. Louis: Mosby, 1996; 654.
9. RizkB, MeagherS, FisherAM. Ovarian hyperstimulation syndrome and cerebrovascular accidents. Hum Reprod 1990; 5: 697–8.
10. RizkB. Ovarian hyperstimulation syndrome. In: StuddJ, ed. Progress in Obstetrics and Gynecology. Vol 11, Chapter 18. Edinburgh: Churchill Livingstone, 1995; 311–49.
11. Dahl-LyonsCA, WheelerCA, FrishmanGN, et al. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. Hum Reprod 1994; 9: 792–9.
12. MathurRS, AkandeAV, KeaySD, et al. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 2000; 73(5): 901–7.
13. RizkB. Genetics of ovarian hyperstimulation syndrome. Reprod Biomed Online. 2009; 19(1): 14–27.
14. AboulgharMA, MansourRT. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum Reprod Update 2003; 9: 275–89.
15. RizkB, AboulgharMA. Classification, pathophysiology and management of ovarian hyperstimulation syndrome. In: BrinsdenP, ed. A Textbook of In Vitro Fertilization and Assisted Reproduction. 2nd edn. Chapter 9. Carnforth, UK: Parthenon, 1999, Chapter 11, 131–55.
16. RizkB, AboulgharMA, SmitzJ, Ron-ElR. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update 1997; 3: 255–66.
17. PellicerA, AlbertC, MercaderA, et al. The pathogenensis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin 1-β, interleukin-6 and vascular endothelial growth factor. Fertil Steril 1999; 71: 482–9.
18. RizkB, SmitzJ. Ovarian hyperstimulation syndrome after superovulation for IVF and related procedures. Hum Reprod 1992; 7: 320–7.
19. DelvigneA, DuboisM, BatteuB, et al. The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicenter study. II. Multiple discriminant analytes for risk prediction. Hum Reprod 1993; 8: 1361–6.
20. Perez MayorgaM, GromollJ, BehreM, et al. Ovarian response to follicle stimulating hormona (FSH) stimulation depends on the FSH receptor genotype. J Clin Endocrinol Metab 2000; 85: 3365–9.
21. De CastroR, RuizR, MontoroL, et al. Role of follicle stimulating hormone receptor ser680Asn polymorphism in the efficacy of follicle stimulating hormone. Fertil Steril 2003; 80: 571–6.
22. DaelemansC, SmitsG, de MaerlelaerV, et al. Prediction of severity of symptoms in iatrogenic ovarian hyperstimulation syndrome by follicle stimulating hormone receptor Ser680Asn polymorphism. J Clin Endocrinol Metab 2004; 89: 6310–15.
23. DanningerB, BrunnerM, ObrucaA, et al. Prediction of ovarian hyperstimulation syndrome of baseline ovarian volume prior to stimulation. Hum Reprod 1996; 11: 1597–9
24. LassA, VassilievA, DecosterdG, et al. Relationship of baseline ovarian volume to ovarian response in World Health Organization Group II anovulatory patients who underwent ovulation induction with gonadotropins. Fertil Steril 2002; 78: 265–9.
25. RizkB, NawarMG. Ovarian hyperstimulation syndrome. In: SerhalP, OvertonC, eds. Good Clinical Practice in Assisted Reproduction. Chapter 8. Cambridge: Cambridge University Press, 2004; 146–66.
26. RizkB. Complications of ovulation induction. II Ovarian hyperstimulation syndrome, ovarian torsion. In: DickeyRP, BrinsdenPR, PyrzakR, eds. Manual of Intrauterine Insemination and Ovulation Induction. Chapter 15. Cambridge: Cambridge University Press, 2010; 152–60.
27. TalJ, FazB, SambergI, et al. Ultrasonographic and clinical correlates of menotrophin versus sequential clomiphene citrate: menotrophin therapy for induction of ovulation. Fertil Steril 1985; 4: 342–9.
28. BlanksteinJ, ShalevJ, SaadonT, et al. Ovarian hyperstimulation syndrome prediction by number and size of preovulatory ovarian follicles. Fertil Steril 1987; 47: 597–602.
29. KweeJ, EltingM, SchatsR, et al. Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilization. Reprod Biol Endocrinol 2007, 5: 9.
30. MoohanJM, CurcioK, LeoniM, et al. Low intraovarian vascular resistance: a marker for severe ovarian hyperstimulation syndrome. Fertil Steril 1997; 57: 728–32.
31. RizkB. Prevention of ovarian hyperstimulation syndrome: the Ten Commandments. Presented at the European Society of Human Reproduction and Embryology Symposium, Tel Aviv, Israel, 1993; 1–2.
32. RizkB.Prevention of ovarian hyperstimulation syndrome. In: RizkB, ed. Ovarian Hyperstimulation Syndrome. Chapter 7. Cambridge: Cambridge University Press, 2006; 130–99.
33. BussoCE, Garcia-VelascoJA, GomezR, et al. Ovarian hyperstimulation syndrome. In: RizkB, Garcia-VelascoJA, SallamH, MadrigiannakisA, eds. Infertility and Assisted Reproduction. Chapter 27. Cambridge: Cambridge University Press, 2008; 243–57.
34. Garcia-VelascoJA, ZunigaA, PachecoA, et al. Coasting acts through downregulation of VEGF gene expression and protein secretion. Hum Reprod 2004; 19: 1530–8.
35. Garcia-VelascoJA, IsazaB, QueaG, et al. Coasting for the prevention of ovarian hyperstimulation syndrome: much to do about nothing?Fertil Steril 2006; 85: 547–54.
36. GomezR, SimonC, RemohiJ, et al. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rate, and this effect is prevented by receptor blockade. Endocrinology 2002; 143(11): 4339–48.
37. GomezR, Gonzalez-IzquierdoM, ZimmermannRC, et al. Low dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 2006; 147: 5400–11.
38. AlvarezC, Marti-BonmatiL, Novella-MaestreE, et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 2007; 92: 2931–7.
39. AlvarezC, Alonso-MurielA, GarciaG, et al. Implantation is apparently unaffected by the dopamine agonist cagergoline when administered to prevent ovarian hyperstimulation in women undergoing assisted reproduction treatment: a pilot study. Hum Reprod 2007; 22(12): 3210–14.
40. Garcia-VelascoJA. How to avoid ovarian hyperstimulation syndrome: a new indication for dopamine agonists. RBM Online 2009; 18(2): 71–5.
41. CarizzaC, AbdelmassihVG, AbdelmassihS, et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. RBM Online 2008; 17(6): 751–5.
42. RizkB, AboulgharMA. Modern magagement of ovarian hyperstimulation syndrome. Hum Reprod 1991; 6: 1082–7.
43. AboulgharMA, MansourRT, SerourGI, et al. Ultrasonically guided vaginal aspiration of ascites in the treatment of ovarian hyperstimulation syndrome. Fertil Steril 1990; 53: 933–5.
44. RizkB, AboulgharMA. Ovarian hyperstimulation syndrome. In: AboulgharMA, Rizk, B, eds. Ovarian Stimulation. Cambridge: Cambridge University Press, 2010.
45. ChenDC, YangJ, Chao, K, et al. Effects of repeated abdominal paracentesis on uterine and intraovarian haemodynamics and pregnancy outcome in severe ovarian hyperstimulation syndrome. Hum Reprod 1998; 13(8): 2077–81.
46. Al-RamahiM, LeaderA, ClamanP, et al. A novel approach to the treatment of ascites associated with ovarian hyperstimulation syndrome. Hum Reprod 1997; 12: 2614–16.
47. AbuzeidMI, NassarZ, MassaadZ, et al. Pigtail catheter for the treatment of ascites associated with ovarian hyperstimulation syndrome. Hum Reprod 2003; 18: 370–3.
48. DelbaereA, SmitsG, OlatunbosunO, PiersonR, VassartG, CostagliolaS. New insights into the pathophysiology of ovarian hyperstimulation syndrome. What makes the difference between spontaneous and iatrogenic syndrome?Hum Reprod 2004; 19(3):486–9.
49. ZaidiJ, CampbellS, PittrofR, et al. Ovarian stromal blood flow in women with polycystic ovaries – a possible new marker for diagnosis?Hum Reprod 1995;10(8):1992–6.
50. JacobsHS. Polycystic ovary syndrome. In: StencheverM, MishellD, eds. Atlas of Clinical Gynecology. Volume III, Reproductive Endocrinology. Chapter 5. Philadelphia: Current Medicine, 1999; 53.